Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases

A multicenter study from Turkey

Tiraje Celkan, Su Berrak, Elif Kazanci, Emel Özyürek, Şule Ünal, Canan Uçar, Şebnem Yilmaz, Aytemiz Gürgey

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

This study evaluates the clinical and laboratory data of children with secondary hemophagocytic lymphohistiocytosis (sHLH) related to malignancy. Charts of patients who met the diagnostic criteria for sHLH associated with malignancy between January 2000-2006 at six different hospitals in Turkey were reviewed retrospectively. The diagnosis of HLH had been established by bone marrow aspiration in 27 patients, cerebrospinal fluid and bone marrow aspiration in one patient and lung-liver biopsy in another. Twenty-nine children were diagnosed as having sHLH related to malignancy. Twenty cases (18 ALL and 2 AML) with acute leukemia (10 girls/10 boys, median age: 8 years [3-14 years]) were found to have sHLH. Five patients with acute leukemia had HLH at the time of diagnosis (Group 1a), and 15 patients with acute leukemia were diagnosed as having sHLH during therapy (Group 1b), namely reactive sHLH associated with the chemotherapy. Nine patients, including two cases each of rhabdomyosarcoma, neuroblastoma, Hodgkin disease, and non-Hodgkin lymphoma (NHL) and one case with Langerhans cell histiocytosis, were diagnosed as having concomitant hemophagocytosis at the initial evaluation of the tumor (Group 2). Fever, anemia, and hypertriglyceridemia were present in all sHLH cases of all three groups. Hepatomegaly was detected in 60.0%, 73.3%, and 88.8% of the three groups, respectively. Splenomegaly was more frequent in patients of Groups 1a (60.0%) and 2 (88.8%) than in those of Group 1b, the reactive ones (13.3%). Hypofibrinogenemia was detected in all patients of Group 1a and Group 2. Low level of fibrinogen was present in 91.6%% of patients in Group 1b. All patients in Group 1b (100%) had neutropenia and thrombocytopenia. Neutropenia was found at rates of 60.0% and 55.5% in Group 1a and Group 2, respectively. Thrombocytopenia was detected in 80.0% of patients in Group 1a and 77.7% in Group 2. The overall mortality rate was 34.4% (10 cases) in our series of 29 children with sHLH; 50% of deaths were directly attributable to HLH. Pediatric malignancy-associated HLH patients have been commonly described as case presentations or in a review of the literature. We believe that our cohort, compiling 29 children regarding the association between malignancy and HLH, will be useful for pediatricians who are interested in this still mysterious topic.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalTurkish Journal of Pediatrics
Volume51
Issue number3
StatePublished - 2009
Externally publishedYes

Fingerprint

Hemophagocytic Lymphohistiocytosis
Turkey
Multicenter Studies
Pediatrics
Neoplasms
Leukemia
Neutropenia
Thrombocytopenia
Bone Marrow
Langerhans Cell Histiocytosis
Hepatomegaly
Rhabdomyosarcoma
Hypertriglyceridemia
Splenomegaly
Group Psychotherapy
Hodgkin Disease
Neuroblastoma
Non-Hodgkin's Lymphoma
Fibrinogen
Cerebrospinal Fluid

Keywords

  • Acute leukemia
  • Chemotherapy-related
  • Hemophagocytic lymphohistiocytosis
  • Malignancy
  • Solid tumors

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Celkan, T., Berrak, S., Kazanci, E., Özyürek, E., Ünal, Ş., Uçar, C., ... Gürgey, A. (2009). Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: A multicenter study from Turkey. Turkish Journal of Pediatrics, 51(3), 207-213.

Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases : A multicenter study from Turkey. / Celkan, Tiraje; Berrak, Su; Kazanci, Elif; Özyürek, Emel; Ünal, Şule; Uçar, Canan; Yilmaz, Şebnem; Gürgey, Aytemiz.

In: Turkish Journal of Pediatrics, Vol. 51, No. 3, 2009, p. 207-213.

Research output: Contribution to journalArticle

Celkan, T, Berrak, S, Kazanci, E, Özyürek, E, Ünal, Ş, Uçar, C, Yilmaz, Ş & Gürgey, A 2009, 'Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: A multicenter study from Turkey', Turkish Journal of Pediatrics, vol. 51, no. 3, pp. 207-213.
Celkan T, Berrak S, Kazanci E, Özyürek E, Ünal Ş, Uçar C et al. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: A multicenter study from Turkey. Turkish Journal of Pediatrics. 2009;51(3):207-213.
Celkan, Tiraje ; Berrak, Su ; Kazanci, Elif ; Özyürek, Emel ; Ünal, Şule ; Uçar, Canan ; Yilmaz, Şebnem ; Gürgey, Aytemiz. / Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases : A multicenter study from Turkey. In: Turkish Journal of Pediatrics. 2009 ; Vol. 51, No. 3. pp. 207-213.
@article{d805519c4144404f8602ce8f2284f70d,
title = "Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: A multicenter study from Turkey",
abstract = "This study evaluates the clinical and laboratory data of children with secondary hemophagocytic lymphohistiocytosis (sHLH) related to malignancy. Charts of patients who met the diagnostic criteria for sHLH associated with malignancy between January 2000-2006 at six different hospitals in Turkey were reviewed retrospectively. The diagnosis of HLH had been established by bone marrow aspiration in 27 patients, cerebrospinal fluid and bone marrow aspiration in one patient and lung-liver biopsy in another. Twenty-nine children were diagnosed as having sHLH related to malignancy. Twenty cases (18 ALL and 2 AML) with acute leukemia (10 girls/10 boys, median age: 8 years [3-14 years]) were found to have sHLH. Five patients with acute leukemia had HLH at the time of diagnosis (Group 1a), and 15 patients with acute leukemia were diagnosed as having sHLH during therapy (Group 1b), namely reactive sHLH associated with the chemotherapy. Nine patients, including two cases each of rhabdomyosarcoma, neuroblastoma, Hodgkin disease, and non-Hodgkin lymphoma (NHL) and one case with Langerhans cell histiocytosis, were diagnosed as having concomitant hemophagocytosis at the initial evaluation of the tumor (Group 2). Fever, anemia, and hypertriglyceridemia were present in all sHLH cases of all three groups. Hepatomegaly was detected in 60.0{\%}, 73.3{\%}, and 88.8{\%} of the three groups, respectively. Splenomegaly was more frequent in patients of Groups 1a (60.0{\%}) and 2 (88.8{\%}) than in those of Group 1b, the reactive ones (13.3{\%}). Hypofibrinogenemia was detected in all patients of Group 1a and Group 2. Low level of fibrinogen was present in 91.6{\%}{\%} of patients in Group 1b. All patients in Group 1b (100{\%}) had neutropenia and thrombocytopenia. Neutropenia was found at rates of 60.0{\%} and 55.5{\%} in Group 1a and Group 2, respectively. Thrombocytopenia was detected in 80.0{\%} of patients in Group 1a and 77.7{\%} in Group 2. The overall mortality rate was 34.4{\%} (10 cases) in our series of 29 children with sHLH; 50{\%} of deaths were directly attributable to HLH. Pediatric malignancy-associated HLH patients have been commonly described as case presentations or in a review of the literature. We believe that our cohort, compiling 29 children regarding the association between malignancy and HLH, will be useful for pediatricians who are interested in this still mysterious topic.",
keywords = "Acute leukemia, Chemotherapy-related, Hemophagocytic lymphohistiocytosis, Malignancy, Solid tumors",
author = "Tiraje Celkan and Su Berrak and Elif Kazanci and Emel {\"O}zy{\"u}rek and Şule {\"U}nal and Canan U{\cc}ar and Şebnem Yilmaz and Aytemiz G{\"u}rgey",
year = "2009",
language = "English (US)",
volume = "51",
pages = "207--213",
journal = "Turkish Journal of Pediatrics",
issn = "0041-4301",
publisher = "Turkish Journal of Pediatrics",
number = "3",

}

TY - JOUR

T1 - Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases

T2 - A multicenter study from Turkey

AU - Celkan, Tiraje

AU - Berrak, Su

AU - Kazanci, Elif

AU - Özyürek, Emel

AU - Ünal, Şule

AU - Uçar, Canan

AU - Yilmaz, Şebnem

AU - Gürgey, Aytemiz

PY - 2009

Y1 - 2009

N2 - This study evaluates the clinical and laboratory data of children with secondary hemophagocytic lymphohistiocytosis (sHLH) related to malignancy. Charts of patients who met the diagnostic criteria for sHLH associated with malignancy between January 2000-2006 at six different hospitals in Turkey were reviewed retrospectively. The diagnosis of HLH had been established by bone marrow aspiration in 27 patients, cerebrospinal fluid and bone marrow aspiration in one patient and lung-liver biopsy in another. Twenty-nine children were diagnosed as having sHLH related to malignancy. Twenty cases (18 ALL and 2 AML) with acute leukemia (10 girls/10 boys, median age: 8 years [3-14 years]) were found to have sHLH. Five patients with acute leukemia had HLH at the time of diagnosis (Group 1a), and 15 patients with acute leukemia were diagnosed as having sHLH during therapy (Group 1b), namely reactive sHLH associated with the chemotherapy. Nine patients, including two cases each of rhabdomyosarcoma, neuroblastoma, Hodgkin disease, and non-Hodgkin lymphoma (NHL) and one case with Langerhans cell histiocytosis, were diagnosed as having concomitant hemophagocytosis at the initial evaluation of the tumor (Group 2). Fever, anemia, and hypertriglyceridemia were present in all sHLH cases of all three groups. Hepatomegaly was detected in 60.0%, 73.3%, and 88.8% of the three groups, respectively. Splenomegaly was more frequent in patients of Groups 1a (60.0%) and 2 (88.8%) than in those of Group 1b, the reactive ones (13.3%). Hypofibrinogenemia was detected in all patients of Group 1a and Group 2. Low level of fibrinogen was present in 91.6%% of patients in Group 1b. All patients in Group 1b (100%) had neutropenia and thrombocytopenia. Neutropenia was found at rates of 60.0% and 55.5% in Group 1a and Group 2, respectively. Thrombocytopenia was detected in 80.0% of patients in Group 1a and 77.7% in Group 2. The overall mortality rate was 34.4% (10 cases) in our series of 29 children with sHLH; 50% of deaths were directly attributable to HLH. Pediatric malignancy-associated HLH patients have been commonly described as case presentations or in a review of the literature. We believe that our cohort, compiling 29 children regarding the association between malignancy and HLH, will be useful for pediatricians who are interested in this still mysterious topic.

AB - This study evaluates the clinical and laboratory data of children with secondary hemophagocytic lymphohistiocytosis (sHLH) related to malignancy. Charts of patients who met the diagnostic criteria for sHLH associated with malignancy between January 2000-2006 at six different hospitals in Turkey were reviewed retrospectively. The diagnosis of HLH had been established by bone marrow aspiration in 27 patients, cerebrospinal fluid and bone marrow aspiration in one patient and lung-liver biopsy in another. Twenty-nine children were diagnosed as having sHLH related to malignancy. Twenty cases (18 ALL and 2 AML) with acute leukemia (10 girls/10 boys, median age: 8 years [3-14 years]) were found to have sHLH. Five patients with acute leukemia had HLH at the time of diagnosis (Group 1a), and 15 patients with acute leukemia were diagnosed as having sHLH during therapy (Group 1b), namely reactive sHLH associated with the chemotherapy. Nine patients, including two cases each of rhabdomyosarcoma, neuroblastoma, Hodgkin disease, and non-Hodgkin lymphoma (NHL) and one case with Langerhans cell histiocytosis, were diagnosed as having concomitant hemophagocytosis at the initial evaluation of the tumor (Group 2). Fever, anemia, and hypertriglyceridemia were present in all sHLH cases of all three groups. Hepatomegaly was detected in 60.0%, 73.3%, and 88.8% of the three groups, respectively. Splenomegaly was more frequent in patients of Groups 1a (60.0%) and 2 (88.8%) than in those of Group 1b, the reactive ones (13.3%). Hypofibrinogenemia was detected in all patients of Group 1a and Group 2. Low level of fibrinogen was present in 91.6%% of patients in Group 1b. All patients in Group 1b (100%) had neutropenia and thrombocytopenia. Neutropenia was found at rates of 60.0% and 55.5% in Group 1a and Group 2, respectively. Thrombocytopenia was detected in 80.0% of patients in Group 1a and 77.7% in Group 2. The overall mortality rate was 34.4% (10 cases) in our series of 29 children with sHLH; 50% of deaths were directly attributable to HLH. Pediatric malignancy-associated HLH patients have been commonly described as case presentations or in a review of the literature. We believe that our cohort, compiling 29 children regarding the association between malignancy and HLH, will be useful for pediatricians who are interested in this still mysterious topic.

KW - Acute leukemia

KW - Chemotherapy-related

KW - Hemophagocytic lymphohistiocytosis

KW - Malignancy

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=70350437912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350437912&partnerID=8YFLogxK

M3 - Article

VL - 51

SP - 207

EP - 213

JO - Turkish Journal of Pediatrics

JF - Turkish Journal of Pediatrics

SN - 0041-4301

IS - 3

ER -